S&P 500   3,096.07 (+0.14%)
DOW   27,759.31 (+0.24%)
QQQ   201.67 (+0.06%)
CGC   18.65 (-3.12%)
BABA   182.67 (-2.30%)
GE   11.34 (-0.70%)
F   8.86 (-1.99%)
ACB   3.51 (-1.68%)
BAC   32.83 (-0.79%)
DIS   142.76 (+3.02%)
S&P 500   3,096.07 (+0.14%)
DOW   27,759.31 (+0.24%)
QQQ   201.67 (+0.06%)
CGC   18.65 (-3.12%)
BABA   182.67 (-2.30%)
GE   11.34 (-0.70%)
F   8.86 (-1.99%)
ACB   3.51 (-1.68%)
BAC   32.83 (-0.79%)
DIS   142.76 (+3.02%)
Log in

Akcea Therapeutics Stock Price, Forecast & Analysis (NASDAQ:AKCA)

$19.53
+0.30 (+1.56 %)
(As of 11/13/2019 12:57 PM ET)
Today's Range
$18.63
Now: $19.53
$19.53
50-Day Range
$14.84
MA: $18.08
$20.44
52-Week Range
$13.90
Now: $19.53
$35.82
Volume9,268 shs
Average Volume233,293 shs
Market Capitalization$1.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.87 million
Book Value$3.10 per share

Profitability

Net Income$-225,820,000.00

Miscellaneous

Employees248
Market Cap$1.83 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.


Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.21. The firm earned $20.62 million during the quarter, compared to analyst estimates of $22.54 million. Akcea Therapeutics had a negative return on equity of 33.00% and a negative net margin of 50.71%. Akcea Therapeutics's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.73) EPS. View Akcea Therapeutics' Earnings History.

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Akcea Therapeutics.

What price target have analysts set for AKCA?

4 equities research analysts have issued twelve-month price targets for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $45.00. On average, they expect Akcea Therapeutics' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 79.2% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

What is the consensus analysts' recommendation for Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Has Akcea Therapeutics been receiving favorable news coverage?

Media stories about AKCA stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Akcea Therapeutics.

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the folowing people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Alps Advisors Inc. (0.20%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.

Which major investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.

Which major investors are buying Akcea Therapeutics stock?

AKCA stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View Insider Buying and Selling for Akcea Therapeutics.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $19.53.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.83 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is http://www.akceatx.com/.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]


MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel